While we have been discussing Beta Cell Mass and Function in our clinic text, most of the conversation has been around insulin and what effects the destruction of Beta Cells has on insulin secretion and uptake. There are other hormones that come into play, and are affected even if they …

We all know the benefits of the newer insulins, i.e., faster action times, less peak from the long actings, etc. But the cost, more often than we know, can lead to patients decreasing insulin doses, doing without until the next payday, or doing without it altogether, as we’ve read about. …

In this week's Homerun Slides, we begin to take a look at how the structure of technology's use in outpatient care. Dr. Stanley Schwartz discusses how this might benefit the management of diabetes.

Incretin defect: Oral glucose elicits a greater insulin response than does intravenous glucose. As first demonstrated by Nauck et al., when tested at matched plasma glucose concentrations (iso- glycemic protocol) the oral route of glucose administration induces a robust increment in insulin secretion as compared with the intravenous route. In nondiabetic subjects, such potentiation — named incretin effect — averages 50 – 70% with a standard (75 g) oral glucose load, and increases with the size of the glucose load. As depicted in Figure 24.10, the incretin effect is characteristically lost in patients with T2DM.